NUCRYST Pharmaceuticals believes that its nanocrystalline technology can be developed into drugs to address medical diseases caused by infection and/or inflammation. Through interactions with clinicians using Smith & Nephew's Acticoat™ dressings with SILCRYST™ coating, NUCRYST decided to pursue potential pharmaceuticals products.
NUCRYST has created NPI 32101, nanocrystalline silver in powder form, which can be combined with pharmaceutical carriers such as creams, gels, solutions, or tablets to form prescription drugs. Laboratory studies have demonstrated NPI 32101's anti-inflammatory and antimicrobial properties. NUCRYST's in vitro and in vivo research results suggest that NPI 32101 offers great promise for a range of commercial pharmaceutical products.